Demand for Pharmaceutical Drugs: A Choice Modelling Experiment

Author(s):  
Anna Merino-Castello
2017 ◽  
Vol 27 (5) ◽  
pp. 519-525 ◽  
Author(s):  
Philip Gendall ◽  
Christine Eckert ◽  
Janet Hoek ◽  
Jordan Louviere

BackgroundOn-pack tobacco warnings can deter smoking initiation and provide powerful cessation cues. However, these warnings typically feature graphic health images, which many young adults dismiss as irrelevant. We estimated responses to more diverse warnings and examined how these performed relative to each other.MethodsWe conducted a behavioural likelihood experiment and a choice modelling experiment in which 474 smokers and 476 susceptible non-smokers aged between 16 and 30 years evaluated 12 warnings featuring health, social, financial and cosmetic themes. The choice data were analysed by estimating Sequential-Best-Worst Choice and Scale-Adjusted Latent Class Models.ResultsSmokers found all test warnings aversive, particularly warnings featuring the effect of smoking on vulnerable third parties, including babies and animals, and showing a dying smoker. Susceptible non-smokers found graphic health warnings and a warning that combined graphic health with loss of physical attractiveness, significantly more aversive than other images tested.ConclusionsIllustrating the harms smoking causes to vulnerable groups may reduce the temporal distance and perceived control over smoking that young adults use to rationalise health warnings. Introducing more diverse warnings could recognise heterogeneity within smoker and susceptible non-smoker populations, and complement warnings featuring long-term health harms.


2019 ◽  
Vol 71 ◽  
pp. 530-542 ◽  
Author(s):  
Geoffrey I. Crouch ◽  
Giacomo Del Chiappa ◽  
Richard R. Perdue

2016 ◽  
Vol 2 (4) ◽  
pp. 234-241
Author(s):  
Mohammed Al-Shakka ◽  
Ebtesam Abood ◽  
Adel Al-Dhubhany ◽  
Sami Abdo Radman Aldubai ◽  
Khaled Said ◽  
...  

Because of the almost-instant connection with the welfare and well-being of individuals, pharmaceutical industry stands prominently as a very important factor for the improvement and progress of a healthy productive nation. These days, pharmaceutical industry thrives as one of the largest and exponentially expanding global industries. Nonetheless, millions of people in low income developing countries, have to suffer from the fatal consequences of the inaccessibility and non-availability of essential drugs. This is also happening in Yemen, where the pharmaceutical manufacturers sector have to face up to many challenges. The Yemen Drug Company (YEDCO) was founded in 1964 by the Yemeni government as it collaborated with private investors. It was endorsed as a company with the expertise in the medicinal drug marketing. YEDCO started its work by taking in drugs from foreign companies and then locally marketing and distributing them. In 1982, YEDCO built the first medicinal factory for drugs in Sana’a. Since then, seven companies were set up to manufacture medicines in Yemen. The expanding population has led to the need to have more pharmaceutical products. It may be understandable that pharmaceutical manufacturer companies are also hit by the political crisis in the country. Inadequate amount of fuel and raw material as well as low security status were some of the underlying factors behind these ill-effects in Yemen. Imported drugs make up about nearly 90% % of the pharmaceutical market compared to 10% drugs from the domestic market. This situation has led to an additional burden being shouldered by the national economy, where Yemen spends about US$263 million annually on pharmaceutical drugs, in reference to the national Supreme Drugs Authority. Although there is a very quick growth in the population and drugs consumption, the pharmaceutical industry has not been very active, where global pharmaceutical products play their role dominantly on the domestic market. The pharmaceutical production necessitates skilled human resources like university graduates. By contrast, the government and the private sector should also motivate the pharmaceutical industry and make use of the local employment


2020 ◽  
pp. 42-43
Author(s):  
Andrey S. Khishov ◽  
◽  
Galina I. Burlakova ◽  

Aquaculture production is a promising direction for the development of food production. Like traditional types of animal husbandry, it needs effective medicines for veterinary use, which would ensure not only the well-being of farmed aquatic organisms, but also increase the safety of the fish products and non-fish objects of fishing. The development of measures to control epizootic processes in aquatic organisms is impossible without the creation of new immunological preparations. The development and use of immunobiological drugs will reduce the use of antimicrobial agents. The corresponding set of pharmaceutical drugs was transferred from the traditional veterinary medicine, but due to the peculiarities of the biology of aquatic animals, their immunity and the characteristics of specific pathogens, this could not be done with biological products. The short development time in the aquaculture industry poses current challenges in the form of a lack of basic and applied research for relatively poorly understood groups of new pathogens. The immunological processes associated with the development and intensity of the immune response in aquatic organisms require a detailed study. For domestic aquaculture producers, the analysis and dissemination of the experience accumulated by mankind and the application of advanced developments in this area are even more relevant, since Russia is just beginning its path of intensifying aquaculture production. At the same time, it is clear that the prohibition of the use and monitoring of antimicrobial agents in food products and feed requires a change in the approach to the problem and will lead to the creation of new immunobiological drugs. The market for immunobiological preparations for aquaculture is the most promising for development. In the article, the authors provide data on the development and registration of vaccines for aquaculture in Europe, North and South America.


2008 ◽  
Vol 37 (7) ◽  
pp. 356-362 ◽  
Author(s):  
Jochen Gönsch ◽  
Robert Klein ◽  
Claudius Steinhardt

2020 ◽  
Author(s):  
Jagjit S Soar

he current COVID-19 pandemic now believed to be based on the mutation of the SARS-CoV virus (first reported in 2002) to SARS-CoV-2 emerging in 2019, is naturally causing extreme worry and concern around the world with sometimes mixed and incoherent messages on how to deal with it. There is a plethora of information from previous epidemics caused by other coronaviruses such as severe acute respiratory syndrome, SARS (2002) and Middle East respiratory syndrome MERS (2012) from which we can extrapolate guidance on how to deal with the current pandemic. In the current absence of specific pharmaceutical agents, we propose assessing the extended tools that we already possess in our biological armoury to combat, prevent and control the spread of this virus. Using a set of precise criteria to locate such possible contenders, we conducted literature searches to find compounds that met these criteria. We have now reduced this to a shortlist of three agents that may be the best candidates. We propose vitamin C, vitamin D and Curcumin fit our criteria well. These compounds are widely available to the general public. They are available online and over-the-counter as supplements. Otherwise healthy individuals are safely able to self-administer these agents as a prophylactic to protect themselves and to enhance their immune response. This would be especially desirable for the elderly and at risk groups. These agents can also be used as adjunct therapy, particularly for those who may have early symptoms. This preventative therapy could be implemented whilst awaiting specific pharmaceutical drugs to emerge as a treatment for COVID-19. Our suggested compounds are a highly cost-effective way to potentially reduce the mortality that is regretfully mounting as a result of COVID-19 infection. The biological mode of action and the dosing of these compounds are summarised.


Sign in / Sign up

Export Citation Format

Share Document